Affinage

GSKIP

GSK3B-interacting protein · UniProt Q9P0R6

Length
139 aa
Mass
15.6 kDa
Annotated
2026-06-10
22 papers in source corpus 13 papers cited in narrative 13 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

GSKIP is a small cytosolic A-kinase anchoring protein (AKAP) that functions as a dual-kinase scaffold and negative regulator of GSK3β signaling (PMID:16981698, PMID:27484798). It was first identified as a GSK3β-binding protein bearing a C-terminal GID-like region homologous to the Axin GSK3β-interaction domain; through this region GSKIP competitively blocks GSK3β phosphorylation of primed and non-primed substrates including Axin and β-catenin, driving β-catenin accumulation and Tcf-4 transcriptional activation in the Wnt pathway (PMID:16981698). This GID-like binding engages GSK3β at sites overlapping those used by Axin but distinct from FRATtide, defining its mode of recognition (PMID:20043192). As an AKAP, GSKIP simultaneously binds PKA (via its N-terminal PKA-RII docking residues V41/L45) and GSK3β (via residue L130), and both interactions are required for it to act as a scavenger that recruits the two kinases away from the β-catenin destruction complex, coordinating PKA-mediated stabilizing phosphorylation of β-catenin (Ser-675) and GSK3β-mediated destabilizing phosphorylation (Ser-33/Ser-37/Thr-41) without itself joining the destruction complex (PMID:27484798). The same dual-anchoring architecture assembles a PKA/GSKIP/GSK3β/Drp1 complex in which GSK3β serves a structural rather than catalytic role to promote PKA phosphorylation of Drp1 at Ser637 and consequent mitochondrial elongation (PMID:25920809), and likewise potentiates PKA-mediated Tau phosphorylation at Ser409 (PMID:31640277). In vivo, GSKIP controls GSK3β Ser-9 phosphorylation (and thus GSK3β activity), and its loss causes perinatal lethality with cleft palate and delayed ossification (PMID:26582204); together with ATG2B it is required for hematopoietic stem cell maintenance (PMID:34748402). GSKIP also modulates Nrf2/ARE antioxidant signaling upstream of GSK3β (PMID:32828530) and supports cell migration and EMT/MET-linked growth through the GSK3β/β-catenin axis (PMID:37133713).

Mechanistic history

Synthesis pass · year-by-year structured walk · 13 steps
  1. 2006 High

    Established GSKIP as a GSK3β-binding protein and negative regulator of GSK3β, answering whether a dedicated cytosolic inhibitor of GSK3β substrate phosphorylation exists.

    Evidence Yeast two-hybrid screen, in vitro kinase and peptide competition assays, Tcf-4 reporter in cells

    PMID:16981698

    Open questions at the time
    • Did not define how GSKIP itself is regulated
    • PKA-anchoring function not yet known
    • In vivo relevance untested
  2. 2009 Medium

    Mapped the GSK3β surface used by GSKIP, showing it overlaps the Axin GID site but is distinct from FRATtide, clarifying the structural basis of recognition.

    Evidence GSK3β single-point mutagenesis, binding assays and molecular simulation

    PMID:20043192

    Open questions at the time
    • No high-resolution structure of the complex
    • Functional consequence of distinct binding modes unresolved
  3. 2009 Medium

    Connected GSKIP to neuronal differentiation by showing it controls GSK3β/β-catenin and N-cadherin/β-catenin pools, extending its regulatory role to a cellular phenotype.

    Evidence Overexpression and siRNA with immunofluorescence/Western in differentiating SH-SY5Y cells

    PMID:19830702

    Open questions at the time
    • Mechanism linking β-catenin pools to neurite outgrowth not fully resolved
    • PKA contribution not examined
  4. 2011 Low

    Provided an atomistic binding model for GSKIPtide on GSK3β, supporting an Axin-like rather than FRAT-like binding mode.

    Evidence Molecular dynamics simulation validated against prior mutagenesis

    PMID:21328310

    Open questions at the time
    • Computational only, no new experimental assay
    • No crystallographic confirmation
  5. 2015 High

    Defined GSKIP as the organizer of a PKA/GSKIP/GSK3β/Drp1 complex driving Drp1 Ser637 phosphorylation and mitochondrial elongation, revealing a function beyond Wnt regulation.

    Evidence Domain mutants, siRNA, phosphomimetic rescue and mitochondrial imaging in HEK293 cells

    PMID:25920809

    Open questions at the time
    • Subcellular site of complex assembly not localized
    • Whether GSKIP targets the complex to mitochondria unclear
  6. 2015 High

    Demonstrated in vivo that GSKIP maintains GSK3β Ser-9 phosphorylation required for palatal fusion, establishing a developmental requirement.

    Evidence Conditional knockout mouse with IHC and Western across embryonic stages

    PMID:26582204

    Open questions at the time
    • Tissue-specific contributions not dissected
    • Link between Ser-9 regulation and ossification defect incomplete
  7. 2015 Medium

    Linked GSKIP germline duplication to enhanced hematopoietic differentiation and myeloproliferative neoplasm cooperation, implicating dosage in disease.

    Evidence iPSC and primary hematopoietic cell assays with genetic epistasis to JAK2/MPL/CALR

    PMID:26280900

    Open questions at the time
    • GSKIP vs ATG2B contributions in the duplication not separated here
    • Molecular pathway to TPO sensitization unresolved
  8. 2016 High

    Resolved the dual-anchoring mechanism: GSKIP simultaneously binds PKA and GSK3β to scavenge both kinases from the β-catenin destruction complex, with AKAP220 as a specificity control.

    Evidence PKA- and GSK3β-binding-defective mutants, Co-IP, phosphorylation and Wnt reporter assays

    PMID:27484798

    Open questions at the time
    • Stoichiometry of the scavenged pool unquantified
    • Dynamics of recruitment vs destruction complex not measured
  9. 2018 Medium

    Identified the PKA-RII binding residues V41/L45 as required for the Drp1 complex and uncovered GSKIP dimerization mediated by L130, refining the architecture of the scaffold.

    Evidence Yeast two-hybrid, Co-IP, mutagenesis and molecular modeling

    PMID:29694914

    Open questions at the time
    • Physiological role of dimerization not established
    • No structure of the dimer
  10. 2019 Medium

    Showed GSKIP anchoring enhances PKA-mediated Tau Ser409 phosphorylation, connecting the cAMP/PKA/GSKIP/GSK3β axis to Alzheimer-relevant Tau modification.

    Evidence In vitro kinase reconstitution, GSKIP domain mutants and isogenic iPSC models

    PMID:31640277

    Open questions at the time
    • In vivo Tau pathology not tested
    • Role of GSK3β conformational contribution incompletely defined
  11. 2020 Medium

    Placed GSKIP upstream of GSK3β in Nrf2/ARE antioxidant signaling, extending its regulatory reach to cardioprotection.

    Evidence Overexpression/siRNA with pharmacological GSK3β inhibition and Nrf2/ARE reporter in cardiomyocytes

    PMID:32828530

    Open questions at the time
    • Direct molecular link from GSK3β to Nrf2 not delineated
    • In vivo cardiac relevance untested
  12. 2021 Medium

    Revealed a non-autophagy synergy between GSKIP and ATG2B in HSC maintenance, distinguishing their roles from the autophagy machinery.

    Evidence Single and double knockout mice with HSC flow cytometry and transcriptomics

    PMID:34748402

    Open questions at the time
    • Molecular basis of the GSKIP-ATG2B synergy unknown
    • Link to oxidative phosphorylation gene upregulation mechanistically unresolved
  13. 2023 Medium

    CRISPR knockout linked GSKIP to GSK3β/β-catenin-driven cell growth, migration and EMT/MET via S675/S552 β-catenin phosphorylation, separating these effects from differentiation.

    Evidence CRISPR/Cas9 knockout with rescue, GSEA, β-catenin phospho-Western and migration assays in SH-SY5Y

    PMID:37133713

    Open questions at the time
    • Tumorigenic relevance in vivo not established
    • Mechanism selecting S675/S552 over S33/S37/T41 unclear

Open questions

Synthesis pass · forward-looking unresolved questions
  • How GSKIP's spatial targeting and dimerization determine which downstream branch (Wnt/β-catenin, Drp1/mitochondrial, Tau, Nrf2, HSC) it engages in a given cell type remains unresolved.
  • No structure of full-length GSKIP with both kinases bound
  • Cell-type determinants of branch selection unknown
  • Upstream regulation of GSKIP itself uncharacterized

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0008092 cytoskeletal protein binding 3 GO:0060090 molecular adaptor activity 3 GO:0098772 molecular function regulator activity 2
Localization
GO:0005829 cytosol 2
Pathway
R-HSA-162582 Signal Transduction 2 R-HSA-1266738 Developmental Biology 1
Complex memberships
PKA/GSKIP/GSK3β/Drp1 complex

Evidence

Reading pass · 13 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2006 GSKIP was identified as a GSK3β-binding protein via yeast two-hybrid screen; a 25-amino acid C-terminal region of GSKIP is highly similar to the GSK3β interaction domain (GID) of Axin. In vitro kinase assays showed GSKIP is a GSK3β substrate and that both full-length GSKIP and its C-terminal fragment block phosphorylation of primed and non-primed GSK3β substrates. A synthetic GSKIPtide competes with and blocks phosphorylation of Axin and β-catenin by GSK3β. Overexpression of GSKIP induces β-catenin accumulation in cytoplasm and nucleus and activates Tcf-4 transcriptional activity, defining GSKIP as a negative regulator of GSK3β in the Wnt signaling pathway. Yeast two-hybrid screen, in vitro kinase assay, peptide competition assay, immunofluorescence, Tcf-4 reporter assay Biochemistry High 16981698
2009 GSKIP binding to GSK3β shares overlapping sites (scaffold-binding region I, SBR-I residues 260–300) with AxinGID and FRATtide, as mapped by single-point mutations in GSK3β. GSK3β V267G mutation reduces binding to GSKIP and AxinGID but not FRATtide, while Y288F mutation abolishes FRATtide binding without affecting GSKIP or AxinGID. A novel C-terminal helix region of GSK3β (SBR-II, residues 339–383) is required for FRATtide binding but not GSKIP or AxinGID binding. GSK3β single-point mutagenesis, co-immunoprecipitation/binding assays, molecular simulation Molecular and cellular biochemistry Medium 20043192
2009 In SH-SY5Y neuroblastoma cells, GSKIP overexpression prevents neurite outgrowth, inhibits GSK3β-mediated phosphorylation of tau at Ser396, increases nuclear β-catenin and cyclin D1 levels, and downregulates N-cadherin expression, reducing recruitment of β-catenin to the membrane. siRNA depletion of β-catenin blocks neurite outgrowth, establishing GSKIP as a regulator of the GSK3β/β-catenin and N-cadherin/β-catenin pools during neuronal differentiation. Overexpression, siRNA knockdown, immunofluorescence, Western blotting in SH-SY5Y cells with retinoic acid differentiation Journal of cellular biochemistry Medium 19830702
2011 Molecular dynamics simulation of GSK3β complexed with a peptide derived from GSKIP (GSKIPtide) showed that GSKIPtide binds a hydrophobic pocket formed by an α-helix and an extended loop near the GSK3β C-terminus; this binding mode is closer to AxinGID than to FRATtide. V267G mutation in GSK3β reduces GSKIPtide binding affinity by ~70%, and Y288F abolishes FRATtide binding but does not affect GSKIPtide, consistent with experimental mutagenesis data. Molecular dynamics simulation validated against experimental mutagenesis data Biopolymers Low 21328310
2015 GSKIP forms a working complex PKA/GSKIP/GSK3β/Drp1 that mediates Drp1 Ser637 phosphorylation in the cAMP/PKA/Drp1 axis. GSKIP wild-type overexpression increases Drp1 S637 phosphorylation 7–8-fold versus PKA-binding-defective (V41/L45) and GSK3β-binding-defective (L130) GSKIP mutants under H2O2/forskolin challenge. Silencing either GSKIP or GSK3β (but not GSK3α) dramatically reduces Drp1 S637 phosphorylation. Kinase-dead GSK3β-K85R (retains GSKIP binding) sustains Drp1 phosphorylation, whereas K85M (loses GSKIP binding) does not, indicating GSK3β acts as an anchoring protein rather than a kinase in this complex. Phosphomimetic Drp1 S637D (but not S637A) rescues the elongated mitochondrial morphology lost in GSKIP mutant-overexpressing cells, placing Drp1 downstream of PKA/GSKIP/GSK3β signaling. Site-directed mutagenesis, overexpression, siRNA knockdown, phosphorylation assays, mitochondrial morphology imaging in HEK293 cells Biochimica et biophysica acta High 25920809
2015 GSKIP deficiency in a conditional knockout mouse causes lethality at birth with cleft palate and delayed ossification. At the molecular level, GSKIP loss decreases GSK3β phosphorylation at Ser-9 (starting at E10.5), leading to enhanced GSK3β activity, establishing GSKIP as an in vivo regulator of GSK3β activity required for palatal shelf fusion. Conditional knockout mouse model, immunohistochemistry, Western blotting for GSK3β Ser-9 phosphorylation The Journal of biological chemistry High 26582204
2015 Germline duplication of GSKIP (and ATG2B) enhances hematopoietic progenitor differentiation, including megakaryocyte differentiation, by increasing progenitor sensitivity to thrombopoietin (TPO), and cooperates with acquired JAK2, MPL, and CALR mutations during myeloproliferative neoplasm development, as demonstrated in iPSC and primary cell models. Induced pluripotent stem cell (iPSC) models, primary hematopoietic cell assays, genetic epistasis with JAK2/MPL/CALR mutations Nature genetics Medium 26280900
2016 GSKIP functions as an AKAP that simultaneously binds PKA and GSK3β, and both interactions are required for regulation of β-catenin. GSKIP facilitates PKA-mediated stabilizing phosphorylation of β-catenin at Ser-675 and facilitates GSK3β-mediated destabilizing phosphorylation at Ser-33/Ser-37/Thr-41. GSKIP acts as a scavenger that recruits PKA and GSK3β away from the β-catenin destruction complex without forming a complex with β-catenin itself. AKAP220, which also binds PKA and GSK3β via a conserved GID, did not affect Wnt signaling, indicating specificity of the GSKIP mechanism. Mutant overexpression (PKA-binding and GSK3β-binding defective GSKIP), co-immunoprecipitation, phosphorylation assays, Wnt reporter assays, comparison with AKAP220 The Journal of biological chemistry High 27484798
2018 The PKA-RII binding domain (V41/L45 residues) of GSKIP is required for forming the PKA/GSKIP/GSK3β/Drp1 working complex and for Drp1 Ser637 phosphorylation. Yeast two-hybrid and co-immunoprecipitation show the V41/L45P mutant causes a gain-of-function in GSKIP dimerization that further influences GSK3β binding, while L130 (GSK3β-binding site) mediates GSKIP dimerization. Molecular modeling indicates mammalian GSKIP can form a dimer through the L130 residue rather than V41/L45. Yeast two-hybrid, co-immunoprecipitation, site-directed mutagenesis, molecular modeling Biochimica et biophysica acta. Molecular cell research Medium 29694914
2019 GSKIP anchoring enhances PKA-mediated phosphorylation of Tau at Ser409; overexpression of GSKIP WT produces greater Tau Ser409 phosphorylation than PKA-binding-defective (V41/L45) or GSK3β-binding-defective (L130) mutants. In vitro kinase assays show that the combination of GSK3β with PKA (but not CaMKII) provides a conformational context for Tau Ser409 phosphorylation. In APPWT/D678H iPSC-derived cells, PKA-mediated Tau phosphorylation is enhanced relative to controls, implicating the cAMP/PKA/GSKIP/GSK3β axis in Alzheimer-relevant Tau hyperphosphorylation. In vitro kinase assay, overexpression of GSKIP mutants, CRISPR/Cas9 isogenic iPSC mutants, Western blotting Journal of clinical medicine Medium 31640277
2020 GSKIP overexpression in cardiomyocytes subjected to hypoxia/reoxygenation (H/R) injury upregulates nuclear Nrf2 and increases Nrf2/ARE transcriptional activity associated with increased GSK3β Ser-9 phosphorylation (GSK3β inhibition). Pharmacological GSK3β inhibition rescues the phenotype caused by GSKIP depletion, placing GSKIP upstream of GSK3β in regulating Nrf2/ARE antioxidant signaling. Nrf2 inhibition reverses the cardioprotective effect of GSKIP overexpression. Overexpression, siRNA knockdown, pharmacological GSK3β inhibition, Nrf2/ARE reporter assay, Western blotting in cardiomyocytes Biochemical and biophysical research communications Medium 32828530
2021 Double knockout of Atg2b and Gskip (but not either gene alone) in mice causes severely decreased hematopoiesis, reduction in long-term HSC pool size due to increased cell death, and lethality in utero with anemia. Loss of both genes increases expression of oxidative phosphorylation genes without affecting autophagy, revealing a synergistic role for GSKIP and ATG2B in HSC maintenance through a non-autophagy mechanism. Double and single knockout mouse models, flow cytometry of HSC populations, bone marrow/fetal liver analysis, transcriptomic gene expression Molecular and cellular biology Medium 34748402
2023 CRISPR/Cas9 knockout of GSKIP in SH-SY5Y cells produces a cell aggregation phenotype and reduced cell growth via suppression of GSK3β/β-catenin pathways and cell cycle progression, linked to EMT/MET signaling rather than differentiation. Phosphorylated β-catenin at S675 and S552 (but not S33/S37/T41) translocates to the nucleus in GSKIP-KO cells. Reintroduction of GSKIP into KO cells restores cell migration and tumorigenesis, and neurite outgrowth upon RA treatment is still observed in GSKIP-KO clones. CRISPR/Cas9 knockout, rescue by GSKIP re-expression, gene set enrichment analysis, Western blotting for β-catenin phosphorylation, migration assays Journal of cell communication and signaling Medium 37133713

Source papers

Stage 0 corpus · 22 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2015 Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies. Nature genetics 104 26280900
2006 GSKIP is homologous to the Axin GSK3beta interaction domain and functions as a negative regulator of GSK3beta. Biochemistry 41 16981698
2016 The A-Kinase Anchoring Protein (AKAP) Glycogen Synthase Kinase 3β Interaction Protein (GSKIP) Regulates β-Catenin through Its Interactions with Both Protein Kinase A (PKA) and GSK3β. The Journal of biological chemistry 38 27484798
2020 The long noncoding RNA OTUD6B-AS1 enhances cell proliferation and the invasion of hepatocellular carcinoma cells through modulating GSKIP/Wnt/β-catenin signalling via the sequestration of miR-664b-3p. Experimental cell research 35 32682012
2015 GSKIP- and GSK3-mediated anchoring strengthens cAMP/PKA/Drp1 axis signaling in the regulation of mitochondrial elongation. Biochimica et biophysica acta 29 25920809
2009 GSKIP, an inhibitor of GSK3beta, mediates the N-cadherin/beta-catenin pool in the differentiation of SH-SY5Y cells. Journal of cellular biochemistry 24 19830702
2019 GSKIP-Mediated Anchoring Increases Phosphorylation of Tau by PKA but Not by GSK3beta via cAMP/PKA/GSKIP/GSK3/Tau Axis Signaling in Cerebrospinal Fluid and iPS Cells in Alzheimer Disease. Journal of clinical medicine 20 31640277
2021 Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms. Leukemia 17 34172895
2020 MiR-181c-5p Mitigates Tumorigenesis in Cervical Squamous Cell Carcinoma via Targeting Glycogen Synthase Kinase 3β Interaction Protein (GSKIP). OncoTargets and therapy 17 32547080
2009 Involvement of the residues of GSKIP, AxinGID, and FRATtide in their binding with GSK3beta to unravel a novel C-terminal scaffold-binding region. Molecular and cellular biochemistry 15 20043192
2011 Prediction of the binding mode between GSK3β and a peptide derived from GSKIP using molecular dynamics simulation. Biopolymers 14 21328310
2015 The A-kinase Anchoring Protein GSKIP Regulates GSK3β Activity and Controls Palatal Shelf Fusion in Mice. The Journal of biological chemistry 13 26582204
2015 ATG2B and GSKIP: 2 new genes predisposing to myeloid malignancies. Molecular & cellular oncology 11 27308616
2018 The origin of GSKIP, a multifaceted regulatory factor in the mammalian Wnt pathway. Biochimica et biophysica acta. Molecular cell research 10 29694914
2022 Many faces and functions of GSKIP: a temporospatial regulation view. Cellular signalling 8 35728705
2021 Loss of Atg2b and Gskip Impairs the Maintenance of the Hematopoietic Stem Cell Pool Size. Molecular and cellular biology 5 34748402
2020 GSKIP protects cardiomyocytes from hypoxia/reoxygenation-induced injury by enhancing Nrf2 activation via GSK-3β inhibition. Biochemical and biophysical research communications 4 32828530
2021 Variation in the Ovine Glycogen Synthase Kinase 3 Beta-Interaction Protein Gene (GSKIP) Affects Carcass and Growth Traits in Romney Sheep. Animals : an open access journal from MDPI 3 34573656
2022 Deciphering the evolution of composite-type GSKIP in mitochondria and Wnt signaling pathways. PloS one 2 35051222
2026 MiR-181b-5p facilitates proliferation and migration by regulating GSKIP through ERK/AKT signaling pathways in gastric cancer. International immunopharmacology 0 42208322
2024 MiR-181c-5p Mitigates Tumorigenesis in Cervical Squamous Cell Carcinoma via Targeting Glycogen Synthase Kinase 3β Interaction Protein (GSKIP) [Retraction]. OncoTargets and therapy 0 39140083
2023 GSKIP modulates cell aggregation through EMT/MET signaling rather than differentiation in SH-SY5Y human neuroblastoma cells. Journal of cell communication and signaling 0 37133713

Missed literature

Know a paper Affinage missed for GSKIP? Flag it for the maintainers and the community.

No submissions yet.